Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Bigpharma biomarker dealmaking activity
2.4. Bigpharma not active in biomarkers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type

2.7 Average deal terms for biomarkers
2.7.1 Biomarker headline values
2.7.2 Biomarker upfront payments
2.7.3 Biomarker milestone payments
2.7.4 Biomarker royalty rates

Chapter 3 - Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving bigpharma

Chapter 4 - Bigpharma biomarker deals

4.1. Introduction
4.2. How to use bigpharma biomarker partnering deals

4.3. Bigpharma biomarker partnering company profiles

Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Healthcare
Bayer Schering Pharma
Bayer Vital
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Genzyme Genetics
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Janssen Pharmaceutica NV
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck Sharpe & Dohme
Merck KGaA
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Mylan
Novartis
Novartis Molecular Diagnostics
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Roche Applied Science
Roche Diagnostics
Roche Molecular Systems
Roche NimbleGen
Genentech
Sanofi
Servier
Shionogi
Shire
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson

Chapter 5 - Biomarker dealmaking directory

5.1. Introduction
5.2. Company A-Z

5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed

5.4. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Manufacturing - OEM
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination

5.5. By therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Inflammatory
Metabolic
Musculoskeletal
Oncology
Respiratory

Chapter 6 - Biomarker partnering resource center

6.1. Online biomarker partnering
6.2. Biomarker partnering events
6.3. Further reading on biomarker dealmaking

Appendices

Appendix 1 - Deal type definitions
Appendix 2 - Example biomarker partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Reports

Table of Figures

Figure 1: Biomarker partnering since 2007
Figure 2: Bigpharma - top 50 - biomarker deals 2007 to 2011
Figure 3: Bigpharma diagnostic deal frequency - 2007 to 2011
Figure 4: Inactive bigpharma in biomarkers 2007-2011
Figure 5: Biomarker partnering by deal type since 2007
Figure 6: Biomarker partnering by disease type since 2007
Figure 7: Biomarker partnering by oncology target since 2007
Figure 8: Biomarker deals with a headline value
Figure 9: Biomarker deal headline value distribution, US$million - 2007-2011 - Discovery stage
Figure 10: Biomarker deal headline value distribution, US$million - 2007-2011 - Discovery stage - detail
Figure 11: Biomarker deals with upfront payment values
Figure 12: Biomarker deals with milestone payments
Figure 13: Biomarker deals with royalty rates, %
Figure 14: Top biomarker deals by value since 2007
Figure 15: Top biomarker deals signed by bigpharma value since 2007
Figure 16: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Cardiovascular)
Figure 17: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Central Nervous System)
Figure 18: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dental)
Figure 19: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dermatology)
Figure 20: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Gastrointestinal)
Figure 21: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Genetic disorders)
Figure 22: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Genitourinary)
Figure 23: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hematology)
Figure 24: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hospital care)
Figure 25: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Immunology)
Figure 26: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Infectives)
Figure 27: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Inflammatory)
Figure 28: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Metabolic)
Figure 29: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Musculoskeletal)
Figure 30: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Oncology)
Figure 31: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Respiratory)
Figure 32: Online partnering resources
Figure 33: Forthcoming partnering events
Figure 34: Deal type definitions
Figure 35: Biomarker partnering agreement between GlaxoSmithKline and Response Genetics, May 2010